Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Neoadjuvant Therapy Stories

2014-01-16 08:27:06

Enables physicians and patients to proactively avoid toxicities from treatments unlikely to provide benefit SAN FRANCISCO, Jan.16, 2014 /PRNewswire/ -- Castle Biosciences today announced that study results of a proprietary predictive test for esophageal cancer demonstrated strong accuracy and specificity in identifying patients who are likely to have tumors that are extremely resistant to standard pre-surgical treatment of chemotherapy and radiation. Data from this second...

2013-12-11 12:02:49

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14. "NeoALTTO is a randomized, phase III clinical trial evaluating whether a combination of two HER2-targeted therapies, trastuzumab and lapatinib, given with standard paclitaxel chemotherapy before...

2013-06-12 08:30:30

HINSDALE, Ill., June 12, 2013 /PRNewswire/ -- Wellness House is pleased to announce their annual Chicago suburban symposium, Hot Topics in Breast Cancer, on Saturday June 29. Hot Topics in Breast Cancer 2013 is a free symposium, bringing together top oncologists, surgeons and healthcare professionals in the Chicagoland area to present the latest updates in the treatment of breast cancer. Wellness House welcomes the top doctors and professionals from The University of Chicago Medicine,...

2010-04-21 06:46:45

In research published this week in PLoS Medicine, Jörg Kleeff from Technische Universität Mnchen, and colleagues suggest that patients with apparently locally non-resectable tumors should be included in neoadjuvant protocols. The authors systematically reviewed studies concerning the effects of neoadjuvant therapy on tumor response, toxicity, resection, and survival percentages in pancreatic cancer. Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related...